Stemirna Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2016)

Organization Overview

First Clinical Trial
2018
NCT03468244
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Stemirna Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

covid-19 mrna vaccine (1 trial)

Drugs in Phase 1 Trials (1)

personalized neoantigen vaccine (1 trial)

Drugs in Other Trials (1)

autologous dendritic cells electroporated with wt1 mrna (2 trials)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3